Open house discount agreements Pegfilgrastim ATC L03AA13
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pegfilgrastim, ATC L03AA13
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The discount agreement does not commit AOK Bayern to purchase any volume. The commercial benefit depends entirely on pr...
If a national or regional framework agreement for Pegfilgrastim is concluded through a formal procurement, the open-hou...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2027
- Supply of pharmaceutical products containing Pegfilgrastim (ATC L03AA13)
- Non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V
Show full summary
This is an open-house model (not a standard procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Pegfilgrastim (ATC L03AA13). All eligible pharmaceutical companies can enter into identical, non-negotiable discount agreements. The contract period is from 1 December 2025 to 30 November 2027, with any-time joining possible until 3 October 2027. No estimated value is provided. The procedure is not subject to procurement law, and no selection/award criteria apply – participation is open to all qualified pharmaceutical undertakings.
Risks
The discount agreement does not commit AOK Bayern to purchase any volume. The commercial benefit depends entirely on pr...
If a national or regional framework agreement for Pegfilgrastim is concluded through a formal procurement, the open-hou...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical undertakings (pharmazeutische Unternehmen) are eligible to participate
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of the signed contract including an annex listing the specific medicinal products
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house discount agreements Pegfilgrastim ATC L03AA13
Non-exclusive discount agreement for the active substance Pegfilgrastim (ATC L03AA13) with AOK Bayern. All eligible pharmaceutical companies can join at any time during the contract period.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Pegfilgrastim, ATC L03AA13
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 673779-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The discount agreement does not commit AOK Bayern to purchase any volume. The commercial benefit depends entirely on pr...
If a national or regional framework agreement for Pegfilgrastim is concluded through a formal procurement, the open-hou...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications